Cita APA (7a ed.)

Salek-Ardakani, S., Yang, W., Ding, S., Chen, S., Dominik, P. K., Stanfield, J., . . . Chaparro-Riggers, J. (2021). Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. BMJ Publishing Group.

Cita Chicago Style (17a ed.)

Salek-Ardakani, Shahram, et al. Dual Checkpoint Blockade of CD47 and PD-L1 Using an Affinity-tuned Bispecific Antibody Maximizes Antitumor Immunity. BMJ Publishing Group, 2021.

Cita MLA (8a ed.)

Salek-Ardakani, Shahram, et al. Dual Checkpoint Blockade of CD47 and PD-L1 Using an Affinity-tuned Bispecific Antibody Maximizes Antitumor Immunity. BMJ Publishing Group, 2021.